Alteogen, a Korean biotech company specializing in drug-delivery platform technologies, said Thursday it has filed an international patent application for a technology designed to prolong drug effects by combining multiple active molecules into a single conjugate.
The technology, called long-acting conjugate, builds on Alteogen’s existing platform for attaching drugs to designated sites on antibodies. By linking multiple active molecules in one structure, the company aims to extend a drug’s half-life and therapeutic effect.
If successfully developed, the platform could reduce dosing frequency or lengthen treatment intervals without compromising efficacy, potentially improving patient convenience and adherence.
Alteogen is applying the technology to ALT-M5, its experimental obesity treatment. In animal studies, the candidate showed potential for once-monthly dosing and for limiting weight regain after treatment was stopped, according to the company.
The findings remain preclinical. Alteogen plans to present detailed results at ObesityWeek 2026, the Obesity Society’s annual meeting, in Washington from Nov. 14-17.
“The patented technology can be applied to a range of biopharmaceuticals to develop long-acting products with once-monthly dosing,” Alteogen CEO Jeon Tae-yeon said.
“Based on the animal study results, we will develop ALT-M5 as a differentiated obesity treatment addressing two major unmet needs: monthly dosing and weight rebound after treatment discontinuation.”
jyoungseon8@heraldcorp.com
